Item 7.01 Regulation FD Disclosure.

On May 17, 2022, BioLargo, Inc. published the press release which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In conjunction with a webcast to be presented on May 19, 2022, at 1:00 p.m. Pacific Time, BioLargo, Inc., intends to present the slides attached as Exhibit 99.2, which is incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K and Exhibits 99.1 and 99.2 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01, in the press release attached as Exhibit 99.1, and in the slide presentation attached as Exhibit 99.2 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the information under the heading "Safe Harbor Act" in Exhibit 99.1 attached hereto, and on the first slide under the heading "Safe Harbor Statement" in Exhibit 99.2 attached hereto.

Item 9.01. Financial Statements and Exhibits.



(d)     Exhibits.


Exhibit No.      Description

99.1               Press release

99.2               Presentation slides

104              Cover Page Interactive Data File (embedded within the Inline
                 XBRL document)

© Edgar Online, source Glimpses